← All trials
NCT06519422
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2025
- Primary completion
- Aug 31, 2028
- Completion date
- Sep 30, 2028
- First posted
- Jul 25, 2024
- Last posted
- Jul 25, 2024
- Enrollment
- 4000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- JP Moulton Charitable FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.